Fairmount Funds Management as of Dec. 31, 2025
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 13 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Cogent Biosciences (COGT) | 24.3 | $320M | 9.0M | 35.52 | |
| Apogee Therapeutics (APGE) | 11.8 | $155M | 2.0M | 75.48 | |
| Spyre Therapeutics Com New (SYRE) | 10.0 | $132M | 4.0M | 32.76 | |
| Miragen Therapeutics (VRDN) | 9.3 | $122M | 3.9M | 31.12 | |
| Oruka Therapeutics (ORKA) | 8.5 | $112M | 3.7M | 30.31 | |
| Dianthus Therapeutics (DNTH) | 6.7 | $88M | 2.1M | 41.21 | |
| Zenas Biopharma (ZBIO) | 6.1 | $80M | 2.2M | 36.31 | |
| Nuvalent Inc-a (NUVL) | 5.6 | $73M | 728k | 100.59 | |
| Jade Biosciences Com New (JBIO) | 5.3 | $70M | 4.6M | 15.43 | |
| Enliven Therapeutics (ELVN) | 4.4 | $57M | 3.7M | 15.40 | |
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 4.1 | $54M | 1.3M | 41.25 | |
| Crescent Biopharma (CBIO) | 2.5 | $33M | 2.7M | 11.86 | |
| Inhibikase Therapeutics Com New (IKT) | 1.3 | $18M | 8.6M | 2.05 |
